
News|Articles|November 1, 2024
AAV Production in Culture Biosciences’ 250mL Bioreactors
Author(s)Culture Biosciences
Adeno-associated virus (AAV) is a critical vector in gene therapy, but process robustness and scalability can pose challenges. This whitepaper demonstrates how Culture Biosciences' on-demand fleets of 250mL bioreactors enable large-scale experimentation and real-time data access to optimize upstream processes. Learn how process optimization can increase the fraction of full AAV capsids, accelerating your path to market.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
AI, CRISPR, and mRNA Driving Biotech’s Smartest Decade Yet
2
Conjugation and Regulation Challenges for Advanced Molecules: Part Two of Three with Abzena
3
Top BP Videos of 2025: An Intersection of AI, Innovation, and Compliance
4
FAQ: Understanding Biosimilars, Biobetters, and Interchangeability
5